高级检索
当前位置: 首页 > 详情页

High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.
出处:
ISSN:

摘要:
MicroRNA (miR)-21 has been identified as a novel biomarker of hepatocellular carcinoma (HCC). However, the prognostic value of miR-21 expression in HCC remains controversial. The aim of the present study was to investigate the value of high expression of miR-21 in predicting the prognosis of HCC. Following a search through the PubMed, Science Citation Index, EMBASE and CNKI databases, a total of 9 studies investigating the expression of miR-21 in HCC and the association between high expression of miR-21 and prognosis of HCC were identified. It was observed that high expression of miR-21 was not associated with poor overall survival of all patients with HCC (P=0.52). However, high expression of miR-21 was found to be correlated with poor prognosis of HCC patients undergoing curative resection (hazard ratio = 2.36; P<0.01). It was also demonstrated that high expression of miR-21 was correlated with tumor size >5 cm [odds ratio (OR)=1.53; P=0.04], venous invasion (OR=4.86; P=0.01), TNM stage (OR=3.44; P<0.01) and liver cirrhosis (OR=2.12; P=0.03). It was concluded that miR-21 cannot be considered as a factor complementary to α-fetoprotein, microvascular invasion and advanced tumor stage in predicting the prognosis of all HCC patients. Higher expression of miR-21 may be a promising biomarker associated with certain clinicopathological characteristics of HCC, such as tumor size, venous invasion, TNM stage and liver cirrhosis.

基金:
语种:
PubmedID:
第一作者:
第一作者机构: [1]Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China. [*1]Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Wenhua Road, Nanchong, Sichuan 637000, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46666 今日访问量:3 总访问量:3332 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号